Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Book value per share
Amgen Inc.'s book value per share at the end of fiscal 2025 was 16.1×, up 47.0% from 10.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 26.5×. Over the past ten years it has ranged from 6.8× (fiscal 2022) to 39.9× (fiscal 2016); the current reading is higher than 64% of that period. Amgen Inc. ranks 6th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 16.1× | 47.05% |
| FY2024 | 10.9× | (6.05%) |
| FY2023 | 11.6× | 71.18% |
| FY2022 | 6.8× | (42.11%) |
| FY2021 | 11.8× | (26.79%) |
| FY2020 | 16.1× | 0.42% |
| FY2019 | 16.0× | (15.45%) |
| FY2018 | 18.9× | (45.23%) |
| FY2017 | 34.5× | (13.55%) |
| FY2016 | 39.9× | 7.80% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 26.5× | 22.57% |
| Jun 2026 | 21.6× | 27.18% |
| Mar 2026 | 17.0× | 5.75% |
| Dec 2025 | 16.1× | (9.99%) |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| AZN AstraZeneca PLC compare | 33.4× |
| AMGN Amgen Inc. | 26.5× |
| NVS Novartis AG compare | 19.8× |
| MRK Merck & Co., Inc. compare | 17.0× |
| PFE Pfizer Inc. compare | 15.7× |
| BMY Bristol Myers Squibb Company compare | 11.5× |
| GILD Gilead Sciences, Inc. compare | 10.4× |
| NVO Novo Nordisk A/S compare | 7.8× |
| ABBV AbbVie Inc. compare | −2.6× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement